Technavio logo image: technavio.com A former Mitchell & Co. Outstanding CEO honoree, John Klein serves as chairman of Cambridge Therapeutics, which he founded in 2011 to deliver combination drug therapies. Concurrently, John Klein is the chairman and CEO of the Alpine, NJ-based Bilogix, LLC, through which he provides enterprise performance management (EPM) solutions to business clients to better inform their decision-making processes and improve operational performance. According to Technavio , the EPM application market is expected to grow by more than $2 billion by 2023, which equates to a compound annual growth rate of nearly 9 percent. Technavio has been monitoring the global market since 2015 and presented its findings in its recent 132-page market analysis report. The report states that market growth will be driven by demand for cloud-based EPM solutions in addition to companies seeking to satisfy changing regulations. Given the volume and sensitive nature of data trans
Based in New Jersey, John Klein guides Cambridge Therapeutics as the company offers innovative pharmaceutical industry solutions that improve patient compliance and outcomes. John Klein and his Cambridge Therapeutics team provide a combination of processing software and point-of-care prescription dispensing solutions that enable pharmacies, urgent care centers, hospitals, and private practice physicians to deliver optimal care.